^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMM2902

    i
    Other names: IMM2902, IMM-2902, IMM 2902
    Company:
    ImmuneOnco Biopharma
    Drug class:
    HER2 inhibitor, CD47 inhibitor
    Related drugs:
    19d
    IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=135, Suspended, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting --> Suspended | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial suspension • Trial primary completion date • Metastases
    |
    HER-2 overexpression
    |
    IMM2902
    9ms
    Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. (PubMed, Drug Resist Updat)
    Moreover, IMM2902 demonstrated a high safety profile regarding anemia and non-specific cytokines release. Collectively, our results highlighted a novel therapeutic approach for the treatment of HER2+ BCs and this approach exhibits significant anti-tumor efficacy without causing off-target toxicity in trastuzumab-resistant BC cells.
    Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    Herceptin (trastuzumab) • IMM2902
    over1year
    Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors. (ASCO 2023)
    IMM2902 showed an encouraging preliminary safety, tolerability and anti-tumor activity up to 2.0 mg/kg. The phase I/II study is ongoing. Clinical trial information: ChiCTR20212375.
    Clinical • P1 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • SIRPA (Signal Regulatory Protein Alpha)
    |
    HER-2 expression
    |
    IMM2902
    over1year
    IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 (clinicaltrials.gov)
    P1/2, N=105, Recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 expression
    |
    IMM2902
    over1year
    Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2902, targeting both HER2 and CD47 as cancer immunotherapy (AACR 2023)
    In preclinical research, IMM2902 has demonstrated a much stronger antitumor activity with excellent tolerability in a mouse model of human breast cancer (dose range 3.5 - 10 mg/kg) and a mouse model of human gastric cancer (dose range 1 -18 mg/kg) than that of trastuzumab (targeting HER2 only) alone, IMM01 (a SIRPα-Fc fusion protein) alone, and the combination of trastuzumab and IMM01. Given the strong preclinical antitumor activity as well as the favorable safety profile, IMM2902 may serve as a potent immunotherapy for HER2-expressing cancers via dual blockade of CD47 and HER2. A Phase 1 clinical trial exploring safety, tolerability, and preliminary efficacy of IMM2902 in patients with HER2-expressing advanced solid tumors is currently ongoing in both China (CXSL2101035) and USA (NCT05076591).
    Preclinical • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    HER-2 overexpression • HER-2 expression
    |
    Herceptin (trastuzumab) • IMM2902
    over2years
    IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | Initiation date: Jan 2022 --> May 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    IMM2902
    over2years
    Preclinical development of a bispecific antibody-trap selectively targeting CD47 and HER2 for the treatment of breast as well as gastric cancer (AACR 2022)
    IMM2902 has no impact on hemagglutination, nor does it have significant hemotoxicity following single as well as multiple administrations in non-human primate animals at different dosage. Our study suggests that IMM2902 has the potential to be an alternative promising treatment option for patients with her2-positive cancers refractory to trastuzumab treatment.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD47 (CD47 Molecule) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
    |
    HER-2 positive • CD47 overexpression
    |
    Herceptin (trastuzumab) • IMM2902
    3years
    IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    IMM2902